Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Are 76% off Vistry shares a once-in-a-decade opportunity?

Vistry shares are looking dirt-cheap on some metrics. Is this the kind of rare buying opportunity that only comes around…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Down 10% in a month with a near-7% yield — are Aviva shares the perfect ISA buy?

Harvey Jones says stock market volatility could give investors the opportunity to snap up Aviva shares at a reduced price…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

£5,000 invested in Diageo shares 1 month ago is now worth…

Diageo shares have dipped below £14 recently, taking the one-year fall to 31%. So why has one leading broker turned…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Elon Musk could give Scottish Mortgage shares a huge boost!

Dr James Fox explains why Scottish Mortgage shares could benefit massively as Elon Musk looks to take SpaceX public later…

Read more »

Investing Articles

As Rolls-Royce and Babcock rocket, has the BAE Systems share price finally run out of juice?

Harvey Jones is astonised at recent sluggish performance of the BAE Systems share price and wonders if there is better…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Down 31% and with a P/E of 8.8, is this FTSE 100 share too cheap to ignore?

Berkeley's share price has collapsed to its cheapest in roughly 10 years. Is the FTSE share now too cheap to…

Read more »

Investing Articles

10 dirt-cheap shares to consider after the correction

Investors keen to contribute to their ISA allowance before Sunday's deadline have a brilliant opportunity to buy cheap shares due…

Read more »

UK supporters with flag
Investing Articles

Why I think this super-cheap growth stock will lead the charge when the FTSE 100 recovers

Harvey Jones is seriously excited by this FTSE 100 growth stock but he also cautions that it can be very…

Read more »